Browse the evidence

Strict glycemic control, blood pressure management, and lipid control significantly reduce the risk of microvascular and macrovascular complications in people with existing diabetes.

If you have diabetes, managing your blood sugar, blood pressure, and cholesterol is critical to preventing serious health issues like heart disease, kidney failure, and blindness. Aim for tight control of these three metrics, as doing so can significantly lower your risk of complications.

GLP-1 receptor agonists treat type-2 diabetes and obesity by mimicking the endogenous hormone GLP-1, which stimulates glucose-dependent insulin secretion, slows gastric emptying, and inhibits food intake.

GLP-1 receptor agonists are effective, FDA-approved treatments for type-2 diabetes and obesity. They work by mimicking a natural gut hormone to increase insulin, slow digestion, and reduce appetite. Consult a doctor to see if a GLP-1 based medication is appropriate for your health profile.

Obesity increases the risk of type 2 diabetes mellitus in a curvilinear manner, with relative risk increasing 40-fold at a BMI of 35 kg/m2 compared to a BMI of 22 kg/m2.

Maintaining a healthy body weight is the most effective way to prevent type 2 diabetes. The risk of developing diabetes increases dramatically as your BMI rises, especially above 35 kg/m2. Losing even a modest amount of weight (5-11 kg) can significantly reduce your risk.

Metformin is the first-line therapy for Type 2 Diabetes, improving glycemic control, increasing insulin sensitivity, and reducing cardiovascular risk and mortality.

Metformin is the standard first-line medication for Type 2 Diabetes. It helps lower blood sugar, improves how your body uses insulin, and uniquely protects your heart and blood vessels, potentially extending your life. It is generally well-tolerated, though some people experience stomach upset initially. It is not suitable for those with significant kidney problems.

Reducing sodium intake significantly lowers systolic and diastolic blood pressure in adults and children, with no adverse effects on blood lipids, catecholamine levels, or renal function.

For most adults, reducing sodium intake to less than 2 grams per day (or cutting current intake by at least one-third) will lower blood pressure without harming your kidneys or cholesterol. Focus on reducing processed foods and added salt to achieve this.

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as exenatide, promote progressive weight loss in humans over up to two years while improving glycemic control, distinguishing them from other diabetes treatments that often cause weight gain.

GLP-1 receptor agonists are a highly effective treatment for both diabetes and obesity. They work by mimicking a gut hormone that signals fullness to the brain. Unlike many other diabetes drugs, they help patients lose weight progressively over time.

Daily subcutaneous liraglutide at 3.0 mg significantly increases weight loss in overweight or obese adults with type 2 diabetes compared to placebo when used as an adjunct to lifestyle interventions.

If you have type 2 diabetes and are overweight, adding daily liraglutide (3.0 mg) to your current diet and exercise plan can lead to significant weight loss (about 6% of body weight over 56 weeks) compared to diet and exercise alone. This medication works by reducing appetite. You should discuss the benefits and potential side effects, such as gastrointestinal issues, with your healthcare provider.

Chronic dynamic aerobic endurance training significantly reduces resting and ambulatory blood pressure in both normotensive and hypertensive adults, with the magnitude of reduction being greater in hypertensive individuals.

Engage in moderate-intensity aerobic exercise (like brisk walking, jogging, or cycling) for about 40 minutes, 3 times a week. You do not need to exercise at high intensities to see blood pressure benefits. This routine has been shown to lower blood pressure effectively, with greater benefits for those who already have hypertension. Consistency over several weeks is key.

Testosterone administration in eugonadal men produces a dose-dependent increase in fat-free mass, muscle volume, strength, and power, following a single linear dose-response relationship without evidence of receptor saturation at supraphysiological levels.

If you are a healthy young man with normal testosterone, adding exogenous testosterone will increase your muscle mass and strength in direct proportion to the dose, even at levels far above what your body naturally produces. You do not need to train harder or eat more protein than normal to see these gains, as the hormonal driver is the primary factor. However, higher doses bring higher risks for side effects like acne and negative lipid changes.

Lorcaserin (10 mg twice daily) combined with lifestyle modification produces significantly greater weight loss and maintenance compared to placebo in obese or overweight adults over 2 years.

Take 10mg of Lorcaserin twice daily alongside a structured diet and exercise plan. This medication helps reduce food intake by targeting specific serotonin receptors in the brain. It is most effective when combined with a daily caloric deficit of 600 kcal and 30 minutes of moderate exercise. Monitor for common side effects like headache or nausea, which are generally mild.

Long-acting GLP-1 receptor agonists (liraglutide and semaglutide) improve glycemic control and promote significant weight loss in individuals with type 2 diabetes and obesity by binding to GLP-1 receptors in the pancreas and brain.

GLP-1 agonists like liraglutide and semaglutide are effective treatments for type 2 diabetes and obesity. They work by mimicking a natural hormone to regulate blood sugar and reduce appetite. Liraglutide is approved at 3.0 mg daily for obesity, while semaglutide is being developed for similar uses and oral administration. These drugs target receptors in the pancreas and brain to achieve their effects.

Very-low-carbohydrate ketogenic diets improve glycemic control, insulin sensitivity, and lipid markers in Type 2 Diabetes (T2D) patients, often allowing for the withdrawal of insulin and other medications.

For Type 2 Diabetics, a VLCKD (under 50g carbs) can dramatically improve blood sugar control, insulin sensitivity, and lipid profiles, often allowing for reduced medication needs, sometimes before significant weight loss occurs.

Obesity, particularly abdominal obesity, increases the risk of type 2 diabetes, with risk rising steeply as BMI increases.

Maintaining a healthy BMI is crucial for preventing type 2 diabetes. The risk of developing diabetes increases significantly as BMI rises, with those having a BMI of 35 or higher facing a dramatically higher risk compared to those with a BMI of 22 or lower.

Adding liraglutide (1.2 or 1.8 mg/day) to maximized metformin and thiazolidinedione (TZD) therapy significantly improves glycemic control (A1C, fasting, and postprandial glucose) and induces dose-dependent weight loss in patients with type 2 diabetes.

If you have Type 2 Diabetes and are already taking metformin and a TZD (like rosiglitazone) but your blood sugar isn't controlled, adding liraglutide (1.2 or 1.8 mg once daily) can significantly lower your A1C and help you lose weight. While you might experience some nausea or stomach issues, these are usually temporary and happen mostly in the first few weeks. This combination is effective for improving blood sugar without causing major low blood sugar episodes.

Liraglutide treatment in combination with metformin and TZD leads to significant reductions in systolic blood pressure and favorable changes in lipid profiles (specifically free fatty acids, LDL, and triglycerides) compared to placebo.

If you are taking metformin and a TZD for Type 2 Diabetes, adding liraglutide (1.2 or 1.8 mg once daily) can also help lower your blood pressure and improve your cholesterol levels (specifically LDL and triglycerides). This adds cardiovascular benefits to the blood sugar and weight control benefits. Be aware that you might experience some nausea, but it usually gets better over time.

Liraglutide treatment improves beta-cell function (measured by C-peptide and HOMA-B) and reduces the proinsulin-to-insulin ratio compared to placebo when added to metformin and TZD.

If you are taking metformin and a TZD for Type 2 Diabetes, adding liraglutide (1.2 or 1.8 mg once daily) can help your pancreas work better by improving beta-cell function. This is measured by markers like C-peptide and the proinsulin-to-insulin ratio. While this is a technical benefit, it contributes to better overall blood sugar control.

Liraglutide (1.8 mg/day) added to metformin and sulfonylurea provides superior glycaemic control and significant weight loss compared to insulin glargine in type 2 diabetes, while maintaining a non-inferior hypoglycaemia risk profile.

If your diabetes is not controlled by metformin and a sulfonylurea, adding once-daily liraglutide (1.8 mg) is a highly effective strategy. It lowers blood sugar better than insulin glargine and helps you lose weight, whereas insulin typically causes weight gain. Be prepared for temporary nausea in the first few weeks, which usually subsides. This treatment requires daily injections but offers superior metabolic benefits compared to basal insulin in this context.

In breast cancer survivors specifically, physical activity is associated with significant improvements in insulin-like growth factor-I (IGF-I), fatigue, depression, and specific strength metrics (bench press, leg press).

For breast cancer survivors, regular physical activity may help lower insulin-like growth factor-I levels, which is a potential biomarker for cancer risk, while also reducing fatigue and depression. This supports the general recommendation for exercise but highlights specific hormonal benefits.

Higher current body mass index (BMI) is strongly and continuously associated with an increased risk of developing non-insulin-dependent diabetes in women, with significant risk elevation starting at average weights (BMI 23-23.9 kg/m²).

Maintaining a healthy weight is critical for preventing type 2 diabetes, even if you are not clinically obese. Risk begins to rise noticeably at average weights (BMI 23-24). Avoiding significant weight gain after young adulthood is one of the most effective ways to lower your diabetes risk, as even moderate weight gains (20-35 kg) drastically increase relative risk.

Lowering LDL cholesterol levels directly reduces the incidence of cardiovascular disease events, establishing a causal dose-response relationship where lower levels yield greater benefit.

If you have diabetes, heart disease, or high cardiovascular risk, keeping your LDL cholesterol as low as possible is the most effective way to prevent heart attacks and strokes. Focus on treatments that lower LDL, such as statins and lifestyle changes, as this directly reduces your risk.

Higher levels of physical activity reduce the risk of six specific cancer sites (bladder, breast, colon, endometrial, esophageal adenocarcinoma, gastric cardia) with strong evidence, while moderate evidence supports inverse associations with lung, ovarian, pancreatic, and renal cancers.

Aim for regular physical activity to lower cancer risk. You do not need a specific dose to start; even breaking up long periods of sitting with standing or walking offers benefits. Consistency matters more than intensity for general risk reduction.

Long-chain omega-3 fatty acids (EPA and DHA) provide cardiovascular protection through anti-atherogenic, anti-thrombotic, and anti-inflammatory mechanisms, with benefits observed at intakes around 1g/day.

Aim for 1g of EPA/DHA daily. If you don't eat oily fish, use supplements or seek out fortified foods like omega-3 enriched milk or spreads. This dose is sufficient to improve cardiovascular surrogate markers.

Regular physical activity (aerobic and resistance) is a major therapeutic modality for type 2 diabetes, improving glucose tolerance and insulin sensitivity, but these benefits deteriorate within 72 hours of the last session, necessitating frequent exercise.

To manage type 2 diabetes, you need to exercise regularly because the benefits wear off after about 3 days. Aim for at least 1000 calories of exercise per week, spread over 3-5 days. Start with low-to-moderate intensity (like brisk walking) for 10-15 minutes, gradually building up to 30 minutes. If you have foot problems, try non-weight-bearing exercises like swimming or cycling. Use how you feel (RPE) to gauge intensity if your heart rate response is affected by neuropathy. Consistency is key to keeping your blood sugar and insulin sensitivity improved.

Abdominal obesity, specifically visceral fat accumulation, is independently associated with metabolic disturbances and increased risk of cardiovascular disease and type 2 diabetes, regardless of overall body mass index.

Focus on waist circumference, not just weight. If your waist is large (over 102 cm for men, 88 cm for women), you have higher visceral fat and metabolic risk, even if your BMI is normal. Measure your waist to assess true health risk.